Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer
David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br />
David Rimm, MD, PhD, a pathologist at Yale University School of Medicine and professor in the Department of Pathology and Department of Medical Oncology, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer (TNBC).
A durvalumab (Imfinzi)-based regimen improved outcomes in patients with TNBC compared with chemotherapy alone. These findings were consistent with those of KEYNOTE-522, which evaluated the checkpoint inhibitor pembrolizumab (Keytruda) in a larger population. However, this small trial compared the antibody to PD-L1 ligand as opposed to in comparison with the PD-1 receptor in KEYNOTE-522, says Rimm.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
